Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -24.76 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 189.51 | 573.99 | 446.92 | 76.48 | 24.81 | 108.80 | 240.78 | 21.26 | 69.14 | 7.78 | 42.94 | 20.30 | 45.53 |
| — | +427.6% | +85.6% | +259.8% | -64.1% | +1298.7% | +460.7% | +4.7% | +51.8% | -65.2% | +38.2% | -8.3% | -19.8% | |
| P/B Ratio | 4.88 | 4.16 | 5.22 | 3.61 | 2.79 | 3.85 | 4.04 | 3.18 | 4.00 | 3.77 | 2.05 | 3.08 | 3.73 |
| — | +7.9% | +29.4% | +13.5% | -30.3% | +2.1% | +96.5% | +3.4% | +7.2% | +28.0% | -11.3% | +20.2% | -26.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Kymera Therapeutics, Inc.'s operating margin was -3422.9% in Q4 2025, down 75.6 pp QoQ and down 2330.8 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -1961.0% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 2663.6% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 2763.6% | -2580.7% | 81.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | +2663.6% | -2680.7% | -18.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -891.3% | -3422.9% | -3347.4% | -736.8% | -336.8% | -1092.2% | -1927.9% | -198.5% | -562.2% | -40.3% | -1216.3% | -262.7% | -478.8% |
| — | -213.4% | -73.6% | -271.1% | +40.1% | -2608.1% | -58.5% | +24.4% | -17.4% | +83.2% | -158.8% | +25.9% | -24.7% | |
| Net Margin | -794.4% | -3043.0% | -2973.0% | -667.6% | -296.7% | -956.9% | -1670.3% | -164.0% | -472.0% | -30.0% | -1118.2% | -235.0% | -432.4% |
| — | -218.0% | -78.0% | -307.1% | +37.1% | -3089.1% | -49.4% | +30.2% | -9.2% | +86.1% | -148.4% | +32.8% | -13.4% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.8% | -6.9% | -8.6% | -8.7% | -8.1% | -8.2% | -7.9% | -6.0% | -8.8% | -3.6% | -12.7% | -8.6% | -8.6% |
| — | +15.8% | -8.2% | -44.7% | +7.9% | -125.2% | +37.8% | +30.3% | -2.1% | +47.7% | -34.8% | +11.2% | -4.1% | |
| ROA | -22.9% | -6.1% | -7.4% | -7.5% | -6.9% | -7.0% | -6.7% | -5.0% | -6.7% | -2.5% | -9.3% | -6.5% | -6.7% |
| — | +13.0% | -9.6% | -50.6% | -2.8% | -176.0% | +28.0% | +23.5% | +0.0% | +54.6% | -25.9% | +12.4% | -7.2% | |
| ROIC | -24.9% | -6.6% | -8.5% | -8.4% | -7.0% | -7.2% | -6.9% | -5.4% | -8.1% | -3.8% | -10.1% | -6.9% | -7.4% |
| — | +8.7% | -23.4% | -55.7% | +12.8% | -91.1% | +32.1% | +21.9% | -9.2% | +46.9% | -6.9% | +15.0% | -12.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 39.0% YoY to 10.47x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.09 | 0.09 | 0.11 | 0.11 | 0.10 | 0.13 | 0.12 | 0.21 | 0.20 | 0.17 | 0.15 |
| — | -50.4% | -10.2% | -31.5% | -10.3% | -51.0% | -51.7% | -25.3% | -17.8% | +506.2% | +526.2% | +296.7% | +265.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.47 | 10.47 | 7.38 | 8.32 | 8.49 | 7.53 | 8.55 | 8.45 | 9.57 | 4.73 | 5.95 | 7.06 | 6.65 |
| — | +39.0% | -13.7% | -1.6% | -11.3% | +59.2% | +43.7% | +19.8% | +44.0% | -19.5% | +9.7% | +53.3% | +36.1% | |
| Quick Ratio | 10.47 | 10.47 | 7.38 | 8.32 | 8.49 | 7.53 | 8.55 | 8.45 | 9.57 | 4.73 | 5.95 | 7.06 | 6.65 |
| — | +39.0% | -13.7% | -1.6% | -11.3% | +59.2% | +43.7% | +19.8% | +44.0% | -19.5% | +9.7% | +53.3% | +36.1% | |
| Interest Coverage | -1403.21 | -1418.78 | — | -782.94 | -1033.69 | -1368.73 | -1202.07 | -834.84 | -838.13 | -371.38 | -1402.66 | -903.81 | -824.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonKymera Therapeutics, Inc.'s current P/E is -24.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Kymera Therapeutics, Inc.'s current operating margin is -891.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Kymera Therapeutics, Inc.'s business trajectory between earnings reports.